Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults

Cancer

Volumn 118, Issue 23, 2012, Pages 5929-5936

  Chang, Cindy M ^a   Warren, Joan L ^a   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer; chronic fatigue; etiology; lymphoma

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; GERIATRIC PATIENT; HUMAN; IMMUNOSTIMULATION; KIDNEY CANCER; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MARGINAL ZONE LYMPHOMA; MEDICARE; MOUTH CANCER; PANCREAS CANCER; PHARYNX CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; UNITED STATES;

AGED; AGED, 80 AND OVER; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASMS; ODDS RATIO; RISK; SEER PROGRAM; UNITED STATES;

EID: 84869503380     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27612     Document Type: Article

References (45)

1. Appel S, Chapman J, Shoenfeld Y,. Infection and vaccination in chronic fatigue syndrome: myth or reality? Autoimmunity. 2007; 40: 48-53. (Pubitemid 46332422)
2. Prins JB, van der Meer JW, Bleijenberg G,. Chronic fatigue syndrome. Lancet. 2006; 367: 346-355. (Pubitemid 43151468)
3. Wu L, Van Kaer L,. Natural killer T cells and autoimmune disease. Curr Mol Med. 2009; 9: 4-14.
4. Devanur LD, Kerr JR,. Chronic fatigue syndrome. J Clin Virol. 2006; 37: 139-150. (Pubitemid 44548485)
5. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G,. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev. 2009; 8: 287-291.
6. Ortega-Hernandez OD, Shoenfeld Y,. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann N Y Acad Sci. 2009; 1173: 600-609.
7. Jason LA, Richman JA, Rademaker AW, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999; 159: 2129-2137. (Pubitemid 29483152)
8. Reyes M, Nisenbaum R, Hoaglin DC, et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med. 2003; 163: 1530-1536. (Pubitemid 36835096)
9. Levine PH, Atherton M, Fears T, Hoover R,. An approach to studies of cancer subsequent to clusters of chronic fatigue syndrome: use of data from the Nevada State Cancer Registry. Clin Infect Dis. 1994; 18 (suppl 1): S49-S53. (Pubitemid 24023884)
10. Levine PH, Fears TR, Cummings P, Hoover RN,. Cancer and a fatiguing illness in Northern Nevada-a causal hypothesis. Ann Epidemiol. 1998; 8: 245-249. (Pubitemid 28208942)
11. Levine PH, Peterson D, McNamee FL, et al. Does chronic fatigue syndrome predispose to non-Hodgkin's lymphoma? Cancer Res. 1992; 52 (19 suppl): 5516s-5518s.
12. Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science. 2009; 326: 585-589.
13. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR,. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A. 2009; 106: 16351-16356.
14. Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2006; 2 (3): e25.
15. Knox K, Carrigan D, Simmons G, et al. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science. 2011; 333: 94-97.
16. Paprotka T, Delviks-Frankenberry KA, Cingöz O, et al. Recombinant origin of the retrovirus XMRV. Science. 2011; 333: 97-101.
17. Simmons G, Glynn SA, Komaroff AL, et al. Blood XMRV Scientific Research Working Group (SRWG). Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science. 2011; 334: 814-817.
18. Silverman RH, Das Gupta J, Lombardi VC, et al. Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science. 2011; 334: 176.
19. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (8 suppl): IV-3-IV-18.
20. Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL,. Use of Surveillance, Epidemiology, and End Results-Medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011; 174: 860-870.
21. National Cancer Institute. SEER site recode ICD-O-3 (1/27/2003) definition. http://seer.cancer.gov/siterecode/icdo3-d01272003/.
22. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007; 110: 695-708. (Pubitemid 47105409)
23. Chang CM, Quinlan SC, Warren JL, Engels EA,. Blood transfusions and the subsequent risk of hematologic malignancies. Transfusion. 2010; 50: 2249-2257.
24. Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3069-3075.
25. Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009; 125: 398-405.
26. Landay AL, Jessop C, Lennette ET, Levy JA,. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet. 1991; 338: 707-712.
27. Buchwald D, Komaroff AL,. Review of laboratory findings for patients with chronic fatigue syndrome. Rev Infect Dis. 1991; 13 (suppl 1): S12-S18.
28. Racciatti D, Dalessandro M, Delle Donne L, et al. Study of immune alterations in patients with chronic fatigue syndrome with different etiologies. Int J Immunopathol Pharmacol. 2004; 17 (2 suppl): 57-62.
29. Bach MA, Bach JF,. Imbalance in T cell subsets in human diseases. Int J Immunopharmacol. 1981; 3: 269-273. (Pubitemid 11027813)
30. Buchwald D, Wener MH, Pearlman T, Kith P,. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol. 1997; 24: 372-376. (Pubitemid 27104105)
31. Raison CL, Lin JM, Reeves WC,. Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun. 2009; 23: 327-337.
32. Aoki T, Miyakoshi H, Usuda Y, Herberman RB,. Low NK syndrome and its relationship to chronic fatigue syndrome. Clin Immunol Immunopathol. 1993; 69: 253-265. (Pubitemid 24009265)
33. Fletcher MA, Zeng XR, Maher K, et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One. 2010; 5 (5): e10817.
34. Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB,. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol. 1998; 88: 96-104. (Pubitemid 28360939)
35. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008; 6: 451-458. (Pubitemid 351447318)
36. Erber E, Lim U, Maskarinec G, Kolonel LN,. Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort. Int J Cancer. 2009; 125: 1440-1445.
37. Zhang Y, Holford TR, Leaderer B, et al. Blood transfusion and risk of non-Hodgkin's lymphoma in Connecticut women. Am J Epidemiol. 2004; 160: 325-330. (Pubitemid 39045263)
38. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
39. Hjalgrim H, Engels EA,. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence. J Intern Med. 2008; 264: 537-548.
40. Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987; 139: 3306-3313. (Pubitemid 18021981)
41. Smedby KE, Askling J, Mariette X, Baecklund E,. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med. 2008; 264: 514-527.
42. Silverman RH, Nguyen C, Weight CJ, Klein EA,. The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol. 2010; 7: 392-402.
43. Waugh EM, Jarrett RF, Shield L, et al. The retrovirus XMRV is not directly involved in the pathogenesis of common types of lymphoid malignancy. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2232-2236.
44. Mawle AC, Nisenbaum R, Dobbins JG, et al. Immune responses associated with chronic fatigue syndrome: a case-control study. J Infect Dis. 1997; 175: 136-141. (Pubitemid 27020835)
45. Stewart CC, Cookfair DL, Hovey KM, Wende KE, Bell DS, Warner CL,. Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome. Cytometry B Clin Cytom. 2003; 53: 26-33. (Pubitemid 38297629)